Figure 4
A prognostic model established factors by multivariate analysis of risk factors (age < 45 years old, BMI ≥ 25 kg/m2, TP53 mutation, and elevated LDH) for overall survival after initial metastasis diagnosis, was validated in 56 patients with metastatic cancer harboring CCNE1 amplification who received phase I trial therapy (A) and in 23 patients who did not receive phase I trial therapy (B) Kaplan–Meier curves estimate overall survival after initial phase I trial clinic visit, stratified by risk score (low-risk group with ≤ 1 risk factor and high-risk group with > 1 risk factors).
